Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von BioPharma Dive

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
00:46Lilly to buy injectable drug plant in manufacturing ramp-up
MoIpsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
MoEisai hunts for next Alzheimer's drug with new research pact
MoBristol Myers taps startup to boost cell therapy production
MoPharmas form joint venture to jumpstart Japanese drug research
MoHow can pharma speed time to treatment? Digital tools can help
FrAlvotech deal could heighten biosimilar pressure on Humira
FrRoche wins FDA OK for targeted drug in early lung cancer
Do23andMe CEO plans to take company private
DoVertex begins bid for US approval of non-opioid painkiller
DoCerevel, in 'major surprise,' finds success in late-stage Parkinson's study
DoMetsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo
MiLilly obesity drug shows benefit in sleep disorder study, pointing to new use
MiSage's cognition drug fails in Parkinson's study
MiStelara biosimilar from Alvotech, Teva approved by FDA
MiCanaan hires Pfizer executive, reels in $100M for biotech investing
16.04.J&J sees mixed performance from new multiple myeloma drugs
16.04.Intra-Cellular builds case for depression drug with late-stage trial win
16.04.Cullinan Oncology changes name, pivots to autoimmune disease
16.04.Biotech landlord Alexandria on research clusters and the sector's recovery
15.04.Roche reports survival data for new dual-acting lymphoma drug
15.04.Neumora's schizophrenia drug hit with clinical hold
15.04.Regeneron commits $500M to new venture capital fund
15.04.Ultragenyx says Angelman therapy is working, but safety questions remain
15.04.The growing role for cfHPV-DNA testing in OPSCC therapeutic development